Page values for "WSI24-146-Case-3"

From MGH Learn Pathology

"_pageData" values

_creationDateJuly 31, 2024
_modificationDateAugust 30, 2024
_creatorSi787
_fullText{{ServiceRequestCase |identifier=WSI24-146-Case-3 |intent=order |code=apdidactic |category=409073007 |subject=MGH |requester=Ah1558 |performer=Vn7 |orderDetail=case |locationCode=MGH |access=Public |status=active |origin=CPOE |priority=Routine |basedOn=WSI24-146 |requisition=Thyroid |reasonCode=11F ...
_numRevisions2
_isRedirectNo

"_fileData" values

"ServiceRequest" values

identifierWSI24-146-Case-3
basedOnWSI24-146
requisitionThyroid
intentorder
category409073007
priorityRoutine
codeapdidactic
orderDetailcase
subjectMGH
occurrenceDateTimeAugust 13, 2024 12:00:00 PM
authoredOnJuly 31, 2024 4:07:05 PM
requesterAh1558
performerVn7
locationCodeMGH
reasonCode11F Right Thyroid Nodule
supportingInfoA. THYROID RIGHT LOBE HEMITHYROIDECTOMY (S24-15758 B1 TO B4; 07/10/2024): Solid papillary thyroid carcinoma with focal classic type component 2.5 cm diffusely involving the left thyroid lobe. See note. There is extensive lymphatic invasion with multiple satellite tumor nodules throughout the right lobe and left lobe. No necrosis is identified. No increased mitotic activity. Immunohistochemistry stains performed at the outside institution and are reviewed at the MGH shows that of the tumor cells are positive for TTF-1 as well is the background thyroid is positive for TTF-1 and thyroglobulin. P63 is focally positive within the intralymphatic tumor cells highlighting the squamous metaplasia. p40 estrogen receptor synaptophysin and calcitonin are negative. Immunostain for beta-catenin is negative (membranous stain only). Immunohistochemistry performed at MGH for HBME-1 shows strong membranous immunoexpression of the cells within the numerous foci of papillary thyroid carcinoma. HBME-1 also highlights numerous foci of lymphatic invasion. P53 shows a wild-type pattern. Immunohistochemistry for pan-TRK is focally positive in tumor cells with a background staining suggestive of an NTRK fusion. Subsequent molecular evaluation is recommended. Immunohistochemistry performed to assess for BRAF p.V600E using a variant specific BRAF antibody is negative consistent with an absence of BRAF p.V600E in this tumor. Immunohistochemistry for ALK TR shows a lack of cytoplasmic ALK expression. The finding is unlikely to be associated with an ALK fusion gene product. Immunohistochemistry for RAS p.Q61R is negative in tumor cells and is consistent with absence of RAS family mutations of Q61R type.
specimennull
bodySitenull
sequence3
accessPublic

"Media" values

identifier182641ce-7529-469a-9241-f68349f09255
basedOnWSI24-146-Case-3
partOfWSI24-146
statusactive
typenull
modalitymrxs
viewshow
operatorAh1558
reasonCodeHBME1 B4
bodySitenull
frames1
content182641ce-7529-469a-9241-f68349f09255.mrxs
notenull
subjectnull
identifier765a0d82-a96a-4bf9-a127-06be20ee4bdb
basedOnWSI24-146-Case-3
partOfWSI24-146
statusactive
typenull
modalitymrxs
viewshow
operatorAh1558
reasonCodeHE Surf Recut 4u
bodySitenull
frames2
content765a0d82-a96a-4bf9-a127-06be20ee4bdb.mrxs
notenull
subjectnull

"status" values

statusactive
identifierWSI24-146-Case-3
requesterAh1558
authoredOnJuly 31, 2024 4:07:05 PM